These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1893961)

  • 1. Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow.
    Duerst RE; Rose D; Frantz CN
    Exp Hematol; 1991 Oct; 19(9):863-7. PubMed ID: 1893961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variables affecting the killing of cultured human neuroblastoma cells with monoclonal antibody and complement.
    Duerst RE; Ryan DH; Frantz CN
    Cancer Res; 1986 Jul; 46(7):3420-5. PubMed ID: 3708574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis.
    Slaper-Cortenbach IC; Admiraal LG; van Leeuwen EF; Kerr JM; von dem Borne AE; Tetteroo PA
    Exp Hematol; 1990 Jan; 18(1):49-54. PubMed ID: 2298269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
    Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
    Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of small cell lung cancer cells in vitro from human bone marrow by a monoclonal antibody.
    Okabe T; Kaizu T; Ozawa K; Urabe A; Takaku F
    Cancer Res; 1985 May; 45(5):1930-3. PubMed ID: 2985239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
    Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
    Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-neuroblastoma monoclonal antibodies which do not bind to bone marrow cells.
    Frantz CN; Duerst RE; Ryan DH; Gelsomino NL; Constine LS; Gregory PK
    Prog Clin Biol Res; 1985; 175():485-99. PubMed ID: 3887430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
    Bast RC; De Fabritiis P; Lipton J; Gelber R; Maver C; Nadler L; Sallan S; Ritz J
    Cancer Res; 1985 Feb; 45(2):499-503. PubMed ID: 3967224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro treatment of human acute lymphocytic leukemia cells in bone marrow with a cocktail of monoclonal antibodies.
    Nakamura H; Hirayama F; Tatsumi Y; Tani Y; Kubota Y; Kanakura Y; Oguma S; Ueda T; Shibata H; Masaoka T
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():537-42. PubMed ID: 6596454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow.
    Saarinen UM; Coccia PF; Gerson SL; Pelley R; Cheung NK
    Cancer Res; 1985 Nov; 45(11 Pt 2):5969-75. PubMed ID: 2414004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
    Bast RC; Ritz J; Lipton JM; Feeney M; Sallan SE; Nathan DG; Schlossman SF
    Cancer Res; 1983 Mar; 43(3):1389-94. PubMed ID: 6337707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma-cell reactive antibody and complement.
    Stone MJ; Tong AW; Fay JW; Lee JC
    Cancer Detect Prev; 1988; 12(1-6):621-35. PubMed ID: 3180147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.
    Kvalheim G; Fodstad O; Pihl A; Nustad K; Pharo A; Ugelstad J; Funderud S
    Cancer Res; 1987 Feb; 47(3):846-51. PubMed ID: 3492268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of antibody-complement-mediated killing of tumor cells by hormones.
    Schlager SI; Ohanian SH; Borsos T
    Cancer Res; 1976 Oct; 36(10):3672-7. PubMed ID: 182362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of complement by an automated cell processor enhances cytotoxicity of monoclonal antibody sensitized leukemia cells.
    Howell AL; Fogg-Leach M; Davis BH; Ball ED
    Bone Marrow Transplant; 1989 May; 4(3):317-22. PubMed ID: 2659117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
    Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
    Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung.
    Bernal SD; Mabry M; Stahel RA; Griffin JD; Speak JA
    Cancer Res; 1985 Mar; 45(3):1026-32. PubMed ID: 2982482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An 80,000-kd glycoprotein cell surface antigen found only on nonhematopoietic cells in human bone marrow.
    Iyer J; Duerst RE; Looney JN; Humphries RK; Abboud CN; Frantz CN
    Exp Hematol; 1990 Jun; 18(5):384-9. PubMed ID: 1692535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.